IL10 and acute coronary syndrome: For example, Evolocumab similary decreased pro- and anti-inflammatory circulating cytokines in a pilot study of Chinese population after acute coronary syndrome (8); while PCSK9i therapy has shown to increase anti-inflammatory mediators like IL-10; to reduce of pro-inflammatory cytokines and to impair the ability of leukocytes to attach endothelium, as well as promoting activation of T-regulatory cells in population with FH (9).